Alligator Bioscience provides an update on mitazalimab
Lund, Sweden – 10 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
The Nomination Committee’s proposals regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)
The Nomination Committee of Alligator Bioscience AB (publ) (“Alligator Bioscience”) proposes re-election of Hans-Peter Ostler an ...
Alligator Bioscience AB announces outcome of exercise of warrants series TO 14
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026
Lund, Sweden – 18 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Management intends to subscribe pro rata in Alligator Bioscience’s warrant program TO 14
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience strengthens intellectual property protection for bispecific antibody platform
Lund, Sweden – 10 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22
Lund, Sweden – 2 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henl ...
Exercise price determined for the exercise of warrants series TO 14 in Alligator Bioscience AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Invitation to Alligator Bioscience’s earnings call on 12 February 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno ...